Atara Biotherapeutics (ATRA) Amortization of Deferred Charges (2018)
Atara Biotherapeutics (ATRA) reported Amortization of Deferred Charges of $86000.0 for Q3 2018, up 40.98% quarter-over-quarter from $61000.0 in Q2 2018.
Atara Biotherapeutics (ATRA) Amortization of Deferred Charges (2018) Analysis & Trends
Atara Biotherapeutics has reported Amortization of Deferred Charges for 1 years, with the latest figure at $86000.0 in Q3 2018.
- For the quarter ending Q3 2018, Amortization of Deferred Charges changed N/A year-over-year to $86000.0; the trailing twelve-month figure through Jun 2019 stood at $86000.0 (down 31.2% YoY), and the FY2018 full-year result was $211000.0, changed N/A from the prior year.
- Amortization of Deferred Charges for Q3 2018 stood at $86000.0, up from $61000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $86000.0 in Q3 2018, with the low at $61000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 86,000.00 |
| Sep 30, 2018 | 86,000.00 |
| Jun 30, 2018 | 61,000.00 |
| Jun 30, 2018 | 61,000.00 |
| Mar 31, 2018 | 64,000.00 |
| Mar 31, 2018 | 64,000.00 |